Physician profile
Ananthan Krishnathas
NPI 1891786554
$1,774.03
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $121 · 2021: $442 · 2022: $513 · 2023: $168 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $563.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $311.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $246.18 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $206.84 | 2019-2024 | |
| Shionogi INC | $120.88 | 2023-2024 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $110.10 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.96 | 2021-2022 | |
| Allergan, INC. | $38.75 | 2019-2020 | |
| Abbvie INC. | $28.01 | 2021-2022 | |
| Baxter Healthcare | $25.80 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Melinta Therapeutics, LLC | $23.50 | 2019 | |
| Smith+Nephew, INC. | $17.46 | 2023 | Collagenase Santyl, Regranex |
| Biomerieux INC | $10.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananthan Krishnathas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.